These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 29153485)

  • 1. Morning administration of 0.4U/kg/day insulin glargine 300U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100U/mL in type 1 diabetes.
    Bailey TS; Pettus J; Roussel R; Schmider W; Maroccia M; Nassr N; Klein O; Bolli GB; Dahmen R
    Diabetes Metab; 2018 Feb; 44(1):15-21. PubMed ID: 29153485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
    Heise T; Hövelmann U; Nosek L; Hermanski L; Bøttcher SG; Haahr H
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1193-201. PubMed ID: 26086190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Day-to-Day and Within-Day Variability in Glucose-Lowering Effect Between Insulin Degludec and Insulin Glargine (100 U/mL and 300 U/mL): A Comparison Across Studies.
    Heise T; Kaplan K; Haahr HL
    J Diabetes Sci Technol; 2018 Mar; 12(2):356-363. PubMed ID: 28946756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation.
    Owens DR; S Bailey T; Fanelli CG; Yale JF; Bolli GB
    Diabetes Metab; 2019 Sep; 45(4):330-340. PubMed ID: 30496834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes.
    Shiramoto M; Eto T; Irie S; Fukuzaki A; Teichert L; Tillner J; Takahashi Y; Koyama M; Dahmen R; Heise T; Becker RH
    Diabetes Obes Metab; 2015 Mar; 17(3):254-60. PubMed ID: 25425297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes.
    Heise T; Nørskov M; Nosek L; Kaplan K; Famulla S; Haahr HL
    Diabetes Obes Metab; 2017 Jul; 19(7):1032-1039. PubMed ID: 28295934
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Schiavon M; Visentin R; Giegerich C; Sieber J; Dalla Man C; Cobelli C; Klabunde T
    Diabetes Technol Ther; 2020 Aug; 22(8):553-561. PubMed ID: 32125178
    [No Abstract]   [Full Text] [Related]  

  • 8. New insulin glargine 300 Units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1.
    Becker RH; Dahmen R; Bergmann K; Lehmann A; Jax T; Heise T
    Diabetes Care; 2015 Apr; 38(4):637-43. PubMed ID: 25150159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultra-long pharmacokinetic properties of insulin degludec are comparable in elderly subjects and younger adults with type 1 diabetes mellitus.
    Korsatko S; Deller S; Mader JK; Glettler K; Koehler G; Treiber G; Urschitz M; Wolf M; Hastrup H; Søndergaard F; Haahr H; Pieber TR
    Drugs Aging; 2014 Jan; 31(1):47-53. PubMed ID: 24263619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low within- and between-day variability in exposure to new insulin glargine 300 U/ml.
    Becker RH; Nowotny I; Teichert L; Bergmann K; Kapitza C
    Diabetes Obes Metab; 2015 Mar; 17(3):261-7. PubMed ID: 25425394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and Pharmacodynamic Head-to-Head Comparison of Clinical, Equivalent Doses of Insulin Glargine 300 units · mL
    Lucidi P; Candeloro P; Cioli P; Marinelli Andreoli A; Pascucci C; Gambelunghe A; Bolli GB; Fanelli CG; Porcellati F
    Diabetes Care; 2021 Jan; 44(1):125-132. PubMed ID: 33444161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300U/mL vs glargine 100U/mL in T2DM.
    Roussel R; Ritzel R; Boëlle-Le Corfec E; Balkau B; Rosenstock J
    Diabetes Metab; 2018 Nov; 44(5):402-409. PubMed ID: 29548798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Distinct Prandial and Basal Pharmacodynamics of IDegAsp Observed in Younger Adults Are Preserved in Elderly Subjects with Type 1 Diabetes.
    Brunner M; Pieber T; Korsatko S; Kojzar H; Svendsen AL; Haahr H
    Drugs Aging; 2015 Jul; 32(7):583-90. PubMed ID: 26088815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes.
    Porcellati F; Lucidi P; Candeloro P; Cioli P; Marinelli Andreoli A; Curti G; Bolli GB; Fanelli CG
    Diabetes Care; 2019 Jan; 42(1):85-92. PubMed ID: 30305345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose-lowering effects.
    Haahr H; Sasaki T; Bardtrum L; Ikushima I
    J Diabetes Investig; 2016 Jul; 7(4):574-80. PubMed ID: 27181070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK-1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects.
    Crutchlow MF; Palcza JS; Mostoller KM; Mahon CD; Barbour AM; Marcos MC; Xu Y; Watkins E; Morrow L; Hompesch M
    Diabetes Obes Metab; 2018 Feb; 20(2):400-408. PubMed ID: 28817223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin degludec requires lower bolus insulin doses than does insulin glargine in Japanese diabetic patients with insulin-dependent state.
    Komuro M; Inoue G; Tabata M; Yamada Y; Atsuda K; Matsubara H; Irie J; Uchida J; Nakajima C; Izumi H; Shimada M; Yamada S
    J Diabetes Sci Technol; 2015 May; 9(3):632-8. PubMed ID: 25526758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial.
    Bolli GB; Riddle MC; Bergenstal RM; Wardecki M; Goyeau H; Home PD;
    Diabetes Metab; 2017 Sep; 43(4):351-358. PubMed ID: 28622950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes.
    Heise T; Hermanski L; Nosek L; Feldman A; Rasmussen S; Haahr H
    Diabetes Obes Metab; 2012 Sep; 14(9):859-64. PubMed ID: 22594461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and pharmacodynamic responses of insulin degludec in African American, white, and Hispanic/Latino patients with type 2 diabetes mellitus.
    Hompesch M; Morrow L; Watkins E; Roepstorff C; Thomsen HF; Haahr H
    Clin Ther; 2014 Apr; 36(4):507-15. PubMed ID: 24508419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.